Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

corbus pharmaceuticals holdings inc - CRBP

CRBP

Close Chg Chg %
10.60 -0.80 -7.55%

Open Market

9.80

-0.80 (7.55%)

Volume: 188.26K

Last Updated:

Sep 9, 2026, 10:39 AM EDT

Trade Now

Company Overview: corbus pharmaceuticals holdings inc - CRBP

CRBP Key Data

Open

$10.60

 Day Range

9.77 - 10.72

52 Week Range

7.12 - 20.56

 Market Cap

$214.30M

Shares Outstanding

19.34M

 Public Float

17.28M

Beta

2.64

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$6.18

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

592.25K

  

CRBP Performance

1 Week
 
 0.00%
 
1 Month
 
 8.95%
 
3 Months
 
 35.29%
 
1 Year
 
 16.63%
 
5 Years
 
 -68.96%
 

CRBP Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 10
Full Ratings ➔

About corbus pharmaceuticals holdings inc - CRBP

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

CRBP At a Glance

Corbus Pharmaceuticals Holdings, Inc.
500 River Ridge Drive
Norwood, Massachusetts 02062
Phone 1-617-963-0100 Revenue 0.00
Industry Pharmaceuticals: Major Net Income -78,537,000.00
Sector Health Technology Employees 36
Fiscal Year-end 12 / 2026
View SEC Filings

CRBP Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 0.972
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 0.634
Enterprise Value to Sales N/A
Total Debt to Enterprise Value -0.03

CRBP Efficiency

Revenue/Employee N/A
Income Per Employee -2,181,583.333
Receivables Turnover N/A
Total Asset Turnover N/A

CRBP Liquidity

Current Ratio 8.069
Quick Ratio 8.069
Cash Ratio 7.923

CRBP Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -48.469
Return on Equity -54.176
Return on Total Capital -52.661
Return on Invested Capital -53.873

CRBP Capital Structure

Total Debt to Total Equity 1.107
Total Debt to Total Capital 1.095
Total Debt to Total Assets 0.971
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Corbus Pharmaceuticals Holdings Inc - CRBP

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -100.00%
-
Cost of Goods Sold (COGS) incl D&A
1.49M 641.00K 600.00K 233.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.49M 641.00K 600.00K 233.00K
Depreciation
1.49M 641.00K 600.00K 233.00K
Amortization of Intangibles
- - - -
-
COGS Growth
-9.23% -56.92% -6.40% -61.17%
Gross Income
(1.49M) (641.00K) (600.00K) (233.00K)
Gross Income Growth
-96.41% +56.92% +6.40% +61.17%
Gross Profit Margin
- - - -
-
2022 2023 2024 2025 5-year trend
SG&A Expense
33.35M 44.44M 48.12M 85.08M
Research & Development
16.14M 31.17M 32.22M 70.09M
Other SG&A
17.21M 13.27M 15.90M 14.98M
SGA Growth
-39.62% +33.25% +8.29% +76.80%
Other Operating Expense
- - - -
-
Unusual Expense
- 4.90M 2.58K (1.10M)
EBIT after Unusual Expense
(39.74M) (45.08M) (48.72M) (84.21M)
Non Operating Income/Expense
(476.21K) 3.40M 10.38M 5.67M
Non-Operating Interest Income
- - 6.31M 5.53M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 2.13M 2.92M 1.87M
Interest Expense Growth
+16.48% +37.14% -35.98% -100.00%
Gross Interest Expense
- 2.13M 2.92M 1.87M
Interest Capitalized
- - - -
-
Pretax Income
(42.35M) (44.60M) (40.21M) (78.54M)
Pretax Income Growth
+27.54% -5.33% +9.85% -95.32%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(42.35M) (44.60M) (40.21M) (78.54M)
Minority Interest Expense
- - - -
-
Net Income
(42.35M) (44.60M) (40.21M) (78.54M)
Net Income Growth
+7.22% -5.33% +9.85% -95.32%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(42.35M) (44.60M) (40.21M) (78.54M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(42.35M) (44.60M) (40.21M) (78.54M)
EPS (Basic)
-10.1535 -10.3068 -3.6837 -5.8974
EPS (Basic) Growth
+8.80% -1.51% +64.26% -60.09%
Basic Shares Outstanding
4.17M 4.33M 10.92M 13.32M
EPS (Diluted)
-10.1535 -10.3068 -3.6837 -5.8974
EPS (Diluted) Growth
+8.80% -1.51% +64.26% -60.09%
Diluted Shares Outstanding
4.17M 4.33M 10.92M 13.32M
EBITDA
(33.35M) (44.44M) (48.12M) (85.08M)
EBITDA Growth
+38.64% -33.25% -8.29% -76.80%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 34.00
Number of Ratings 10 Current Quarters Estimate -1.214
FY Report Date 09 / 2026 Current Year's Estimate -5.434
Last Quarter’s Earnings -1.81 Median PE on CY Estimate N/A
Year Ago Earnings -5.90 Next Fiscal Year Estimate -5.513
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 10 10 10 9
Mean Estimate -1.21 -1.32 -5.43 -5.51
High Estimates -0.73 -0.74 -4.06 -2.97
Low Estimate -1.91 -1.74 -6.81 -6.90
Coefficient of Variance -32.08 -25.09 -15.61 -26.13

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 10 10 10
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Corbus Pharmaceuticals Holdings Inc - CRBP

Date Name Shares Transaction Value
Oct 28, 2025 Sean F. Moran Chief Financial Officer 86,294 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $4.26 per share 367,612.44
Oct 28, 2025 Sean F. Moran Chief Financial Officer 73,313 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $17.02 per share 1,247,787.26
Oct 28, 2025 Sean F. Moran Chief Financial Officer 10,386 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 28, 2025 Yuval Cohen Chief Executive Officer; Director 156,847 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $4.26 per share 668,168.22
Oct 28, 2025 Yuval Cohen Chief Executive Officer; Director 138,187 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $17.01 per share 2,350,560.87
Oct 28, 2025 Yuval Cohen Chief Executive Officer; Director 147,160 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $4.26 per share 626,901.60
Oct 28, 2025 Yuval Cohen Chief Executive Officer; Director 138,187 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $17.14 per share 2,368,525.18
Oct 28, 2025 Yuval Cohen Chief Executive Officer; Director 31,079 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 28, 2025 Yuval Cohen Chief Executive Officer; Director 22,106 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Corbus Pharmaceuticals Holdings Inc in the News